为探讨BSD2000 深部相控阵聚能热疗系统(BSD2000)联合化疗治疗局部晚期胰腺癌患者的近期疗效、疼痛及生活质量改善和不良反应, 收集2009 年10 月至2014 年10 月在北京医院肿瘤内科确诊的30 例局部晚期胰腺癌患者, 给予化疗同时联合局部热疗的治疗方法(联合组), 同时选取同期住院治疗30 例局部晚期胰腺癌患者, 仅给予单纯化疗作为对照组(化疗组), 评估两组治疗效果及不良反应, 观察两组在生活质量及疼痛改善方面有无差异。结果显示, 联合组和化疗组的有效率和疾病控制率分别为10%、6.7%和83%、76%, 两组相比无统计学差异(P＞0.05), 联合组治疗后疼痛及生活质量的改善均明显优于化疗组, 差异具有统计学意义(P<0.05)。骨髓抑制和胃肠道反应是最常见的不良反应, 两组相比发生率无明显差异(P＞0.05), 热疗与化疗联合并不增加毒副反应,两组均无严重不良反应发生。结果表明, 在化疗基础上联合热疗可以明显减轻疼痛症状, 提高患者的生活质量, 且治疗简单, 副作用较小, 临床可操作性好, 值得推广。
This study aims to evaluate the short-term efficacy, pain reduction, quality of life (QQL) and toxicity of BSD2000 deep hyperthermia combined with chemotherapy in patients with advanced pancreatic cancer. All cases were diagnosed and treated in Beijing Hospital from October 2009 to October 2014. A total sixty patients with advanced pancreatic cancer were divided into two groups. Thirty patients in the combination therapy group received chemotherapy combined with BSD2000 deep hyperthermia(twice per week). Another thirty patients in the chemotherapy therapy group were only given chemotherapy. Twenty-one days were one cycle. The short-term efficacy, pain relief, QQL and toxicity were evaluated after two cycles. All sixty patients were assessable for response. The response rates for the combination therapy group and the chemotherapy therapy group were 10% and 6.7%, respectively, while the disease control rates for the two groups were 83% and 76%, respectively. There was no significant different between the two groups (P>0.05). The combination group showed significant improvement in pain relief and QQL compared to the control group (P<0.05). There were some mild side effects, such as gas trointestinal toxicities and myelosuppression, but no significant difference between the two groups (P>0.05). There was no severe side effect in the two groups. Even though there was no difference in efficacy, the combination group did show pain reduction, improved QQL and tolerable toxicity. BSD2000 deep hyperthermia combined with chemotherapy in patients with advanced pancreatic cancer is worthily recommended in the clinical application.
[1] Wang P, Meng Z Q, Chen Z, et al. Survival rate of pancreatic cancer in elderly patients[J]. Hepato-gastroenterology, 2008, 55(82/83): 681-686.
[2] 余一祎, 刘天舒. 晚期胰腺癌姑息性化疗进展[J]. 中国癌症杂志, 2009, 19(8): 585-589. Yu Yiyi, Liu Tianshu. Advancedin palliative chemotherapy for advanced pancreat cancer[J]. China Oncology, 2009, 19(8): 585-589.
[3] Wust P, Hidebrandt B, Streenivasa G, et al. Hyperthermia in combined treatment of cancer[J]. Lancet Oncology, 2002, 3(8): 489-497.
[4] Trotti A, Bentzen S M. The need for adverse effects reporting standards in oncology clinical trials[J]. Journal of Clinical Oncology, 2004, 22(1): 19-22.
[5] 孙燕, 周际昌. 临床肿瘤内科学[M]. 北京: 人民卫生出版社, 1997: 45-54.Sun Yan, Zhou Jichang. Medical oncology[M]. Beijing: People's Medical Publishing House, 1997: 45-54.
[6] 张太平, 王天笑, 赵玉沛. 胰腺癌诊断和治疗的瓶颈与对策[J]. 中华消 化外科杂志, 2012, 11(1): 41-44. Zhang Taiping, Wang Tianxiao, Zhao Yupei. Challenges and strategies in diagnosis and treatment of pancreatic cancer[J]. Chinese Journal of Digestive Surgery, 2012, 11(1): 41-44.
[7] Burris H, Moore M J, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first—line therapy for patients with advanced pancreas cancer: A randomized trial[J]. Journal of Clinical Oncology, 1997, 5(6): 2403-2413.
[8] Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: Arandomized, multicenter, phaseⅢ trial of the Swiss Group for clinical cancer research and the central european cooperative oncology group[J]. Journal of Clinical Oncology, 2007, 25(16): 2212-2217.
[9] 彭楠, 赵彼得. 临床肿瘤热疗[M]. 北京: 人民军医出版社, 2002: 66- 68. Peng Nan, Zhao Bide. Clinical tumor hyperthemia[M]. Beijing: People′s Military Medical Press, 2002: 66-68
[10] Maluta S, Schaffer M, Pioli F, et al. Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer: An open- label comparative cohort trial[J]. Strahlentherapie and Onkologic, 2011, 187(10): 619-625.
[11] Yasuda M, Kondo M, Kokura S, et al. Comparison of concomitant gemcitabine chemotherapy and local hyperthermia, gemcitabine monoche motherapy, and local hyperthermia monotherapy for inoerable progressive pancreatic cancer[J]. Journal of Clinical Oncology, 2008, 26(Suppl 1): 15672
[12] Grunhagen D J, de Wilt J H, van Geel A N, et al. Isolated limb perfusion with TNF- alpha and melphalan in locally advanced soft tissue sarcomas of the extremities[J]. Recent Results in Cancer Research, 2009, 179: 257-270.
[13] Bapat A A, Hostetter G, Von Hoff D D, et al. Perineural invasion and associated pain in pancreatic cancer[J]. Nature Reviews Cancer, 2011, 11(10): 695-707.
